---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-26-000018"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:38:57.467434+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Novocure reports Q4 2025 revenues up 8% to $174M; FDA approves Optune Pax for pancreatic cancer

## Summary
- FDA approved Optune Pax for locally advanced pancreatic cancer in Feb 2026; expands addressable market significantly.
- Q4 2025 net revenue $174.4M (+8% YoY); full year $655.4M (+8%). Q4 net loss $24.5M ($0.22 loss per share).
- 2026 guidance: revenue $675-705M; Adjusted EBITDA ($20M)-$0M; Optune Lua/Pax revenue $15-25M.
- Frank Leonard appointed CEO Dec 2025; CMO Nicolas Leupin resigned Feb 2026; CMS billing privileges reinstated.
- Active patients on TTFields therapy globally totaled 4,620 at Dec 31, 2025; GBM prescriptions up 6%.

## SEC filing metadata
- accession: 0001645113-26-000018
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000018/0001645113-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000018/nvcr-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-26-000018
- JSON: https://secwatch.observer/filing/0001645113-26-000018.json
- Plain text: https://secwatch.observer/filing/0001645113-26-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.